Nabriva Therapeutics plc - Ordinary Shares (NBRV) Social Stream
NABRIVA THERAPEUTICS PLC (NBRV) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering NABRIVA THERAPEUTICS PLC.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
NBRV reports an average of 3,183.93% for its upside potential over the past 40 weeks.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
NBRV Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 27 months, NBRV's average broker recommendation rating worsened by 1.4.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for NBRV as an investment opportunity.
- NABRIVA THERAPEUTICS PLC's number of analysts covering the stock is greater than 34.84% of all US stocks.
- NBRV has a lower variance in analysts' estimates than 4.15% of Pharmaceutical Products stocks.
- In the context of stocks in the mid market cap category, NABRIVA THERAPEUTICS PLC's average analyst price target is higher than 92.88% of them.
- NBRV has a higher upside potential (average analyst target price relative to current price) than 434.03% of stocks in the mid market cap category.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to NABRIVA THERAPEUTICS PLC are ANAB, PTGX, and RETA.
What is the outlook for NBRV? Use POWR Ratings for clearer insight into price direction.